Transdermal delivery of antiparkinson agents
AssigneeAcrux DDS Pty Ltd
InventorsKathryn Traci-Jane Klose, Ngan Thi Kim Tran, Timothy Matthias Morgon, Barrie Charles Finnin, Barry Leonard Reed
Life of this patent
Estimating the term…
Abstract
The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.
Claims18
A transdermal drug delivery system comprising:
- (a) a therapeutically effective amount of an antiParkinson agent;
- (b) at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen of formula (I):
- wherein
- R1 is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR3R4;
- R2 is a C8 to C18 alkyl;
- R3 and R4 are each independently hydrogen, lower alkyl or R3 and R4 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring;
- n is 0 or 1, and
- q is 1 or 2,
- wherein, when n is 0 and R1 is NR3 R4, then NR3 R4 is para-substituted, and
- wherein said dermal penetration enhancer is present in an amount of from about 10 to about 10,000 wt % based on the weight of the antiParkinson agent;
- and
- (c) at least one volatile liquid.
Dependencies are inferred from the claim text.